Successful Exit: PerkinElmer Agrees to Acquire SIRION Biotech
SIRION Biotech will continue to grow its position in viral vector technologies for cell and gene therapy as part of PerkinElmer
High-Tech Gründerfonds, Creathor Ventures, KfW and Bayern Kapital announced that they are committed to sell their shares of SIRION Biotech GmbH, a global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. This news comes after PerkinElmer, Inc. announced that it has entered into an agreement to acquire SIRION. The acquisition is expected to close during the third quarter of 2021.
Symbolic image
pixabay.com
In 2007 Creathor Ventures, High-Tech Gründerfonds, Bayern Kapital and KfW syndicated in a first seed financing round of SIRION.
Headquartered in Munich, Germany, privately held SIRION has approximately 50 employees based in Germany, the U.S. and France. The company has established a strong licensing portfolio leveraged by over a dozen major pharmaceutical and biotech players researching more than twenty-five diseases and conditions.
"Our team is excited to work with PerkinElmer to continue to grow our leading position in viral vector technologies for cell and gene therapy. We will benefit greatly from becoming part of the PerkinElmer portfolio, with increased access to genomics analysis, gene editing and base editing technologies, as well as a strong global infrastructure and reach", Dr. Christian Thirion, CEO of SIRION.
"We are very proud to have played a part in SIRION’s successful development. As a seed investor, we are always on the lookout for high-potential technologies prior to market launch as well as highly motivated entrepreneurs and teams. SIRION delivered on all these aspects", Marco Winzer, Partner at High-Tech Gründerfonds.
"SIRION is a great example of founders and management teaming up with experienced investors to bring an early-stage scientific innovation from the academic lab bench to world-wide technology leadership. We are very pleased to have played an active role in this success story", Karlheinz Schmelig, Partner at Creathor Ventures.
"From the very beginning, we have been very impressed with SIRION’s technical knowledge and market expertise, and have been actively supporting the company’s growth over the years as of the earliest stage. We are therefore very pleased with this great success and wish SIRION the very best", Roman Huber, Managing Director at Bayern Kapital.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
